News and Trends 13 Nov 2017 British Biotech Gets PRIME Designation for its Brittle Bones Drug The EMA has awarded PRIME Designation to Mereo BioPharma’s osteogenesis imperfecta drug, a condition for which there is no treatment on the market. Mereo acquires, develops and commercializes therapies for patients with rare diseases. It was set up by Denise Scots-Knight, one of our top women entrepreneurs, in 2015 and already has a market cap […] November 13, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 9 Nov 2017 Meet the Spin-Out Queen Taking on Neurological Diseases Mary Kerr, CEO of NeRRe and Managing Director of KanDy, told us how its approaches could change the face of therapies for neuronal hypersensitivity and women’s health indications. Mary Kerr’s career has taken her through the rigorous world of big pharma, which she says gave her “the skillset… the development, the exposure and the opportunity to work […] November 9, 2017 - 4 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 8 Nov 2017 Interviewing Europe’s Most Intense Investor about Trends in Biotech I interviewed Kate Bingham of SV Health Investors about Alzheimer’s, checkpoint inhibitors, gender diversity and more at BIO Europe. BIO Europe 2017 was off to a racing start on Monday morning when I chatted with Kate Bingham, Managing Partner of SV Health Investors, formerly SV Life Sciences. Since she joined the firm in 1991, she […] November 8, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2017 German Pharma and Biotech Gang Up on NASH in an Exciting Collaboration Boehringer Ingelheim’s fight against liver disease is taking shape, having agreed on a partnership with RNA pioneer MiNA Therapeutics to fight NASH. British biotech, MiNA Therapeutics, has announced a partnership with pharma giant Boehringer Ingelheim to focus on developing compounds to treat fibrotic liver diseases like Non-Alcoholic SteatoHepatitis (NASH). Bringing MiNA on board has given Boehringer Ingelheim access to […] November 8, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2017 British Researchers Find Thought Police to Treat Neurological Disorders Cambridge University scientists have identified a chemical in the brain that blocks unwanted thoughts, offering a new avenue to treat neurological disorders. Researchers at the University of Cambridge have found identified a new process in the brain’s prefrontal cortex that can block our thoughts. The research, published in Nature Communications, demonstrated that the ability to block unwanted thoughts […] November 7, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 2 Nov 2017 Meet the Top Biotech Investor Who Picked His Career By Accident Kevin Johnson, Partner at Medicxi, joined us last week for our Meetup in London. He told us how he ended as an investor despite starting in biotech. Fresh from his PhD at Cambridge, Johnson stepped into biotech and led the development of a number of human antibodies at Cambridge Antibody Technology (CAT). The company was eventually responsible for […] November 2, 2017 - 4 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 27 Oct 2017 Lack of Permanent Academic Roles is Frightening News for PhD Students With Halloween around the corner, PhD students probably felt safe from any nasty surprises for a few more days but their careers in academia may have hit a snag. PhD students work very hard, but surely it is all worth it for the guarantee of a good job at the end of it all? A study […] October 27, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2017 The FDA Recruits British Organs-on-Chips to Speed Up Drug Development CN Bio Innovations and the FDA have entered a research collaboration to better predict drug safety in drug development by using human organs-on-chips. CN Bio Innovations, a spin-out from the University of Oxford, will be working with scientists from the FDA’s Centre for Drug Evaluation and Research with the aim of integrating organ-on-a-chip technology in the […] October 26, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 26 Oct 2017 Meet John Beadle, the Serial Entrepreneur with the Key to Oncolytic Viruses Serial entrepreneur John Beadle is now at the helm of PsiOxus, an Oxford biotech with some promising virus-based cancer treatments. Oncolytic viruses have been around for a while without much to show for themselves besides Amgen’s Imlygic, but PsiOxus, one of our top Oxford biotechs, has some ideas to make them bear fruit. The company […] October 26, 2017 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 25 Oct 2017 British Researchers Develop Clever Nanoparticles to Kill Cancer Cells The University of Surrey has developed nanoparticles that heat up to kill cancer cells, but can then be controlled to protect healthy tissue. Research from the University of Surrey, published in Nanoscale, has been put forward as a new form of thermotherapy. Although it has been available for a long time, thermotherapy’s use is limited by […] October 25, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2017 Update: GSK’s Shingles Vaccines Impresses FDA Panel who Push for its Approval Update (24/10/2017): Shingrix has been approved by the FDA and will cost $280 (€238) for the required two shots, which should be covered by most insurance plans. Originally published on 13/9/2017 An FDA panel voted 11-0 to support the approval of GSK’s new shingles vaccine based on “impressive” efficacy and safety results in a Phase III […] October 24, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2017 British Scientists Prove that it Takes Very Few Mutations to Cause Cancer Researchers in the UK have analyzed over 7,500 tumors and estimate that a very low number of mutations is needed for cancer to develop. Researchers coming out of the prestigious Sanger Institute in Cambridge, UK has estimated that as few as 1 to 10 mutations are required to cause cancer. The study, published in Cell, was […] October 24, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email